End-of-day quote
INDONESIA S.E.
18:00:00 2024-04-25 EDT
|
5-day change
|
1st Jan Change
|
2,320
IDR
|
0.00%
|
|
-0.43%
|
-10.42%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,688,144
|
5,552,712
|
5,715,230
|
7,313,328
|
7,448,760
|
7,015,378
|
Enterprise Value (EV)
1 |
4,261,178
|
4,375,026
|
3,949,573
|
5,758,312
|
6,579,735
|
6,469,271
|
P/E ratio
|
8.71
x
|
9.56
x
|
8.4
x
|
8.63
x
|
8.79
x
|
10.2
x
|
Yield
|
4.29%
|
4.39%
|
9.48%
|
7.59%
|
7.45%
|
-
|
Capitalization / Revenue
|
0.28
x
|
0.25
x
|
0.25
x
|
0.28
x
|
0.27
x
|
0.25
x
|
EV / Revenue
|
0.21
x
|
0.2
x
|
0.18
x
|
0.22
x
|
0.23
x
|
0.23
x
|
EV / EBITDA
|
4.43
x
|
5
x
|
4.36
x
|
4.86
x
|
5.26
x
|
6.16
x
|
EV / FCF
|
10.9
x
|
-38.9
x
|
5.86
x
|
38.3
x
|
-30.3
x
|
40.4
x
|
FCF Yield
|
9.2%
|
-2.57%
|
17.1%
|
2.61%
|
-3.3%
|
2.47%
|
Price to Book
|
0.98
x
|
0.91
x
|
0.87
x
|
1.07
x
|
1.05
x
|
0.97
x
|
Nbr of stocks (in thousands)
|
2,708,640
|
2,708,640
|
2,708,640
|
2,708,640
|
2,708,640
|
2,708,640
|
Reference price
2 |
2,100
|
2,050
|
2,110
|
2,700
|
2,750
|
2,590
|
Announcement Date
|
19-03-29
|
20-04-03
|
21-03-29
|
22-03-31
|
23-03-28
|
24-03-28
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
20,604,487
|
22,226,912
|
22,545,419
|
25,673,757
|
28,027,488
|
28,507,873
|
EBITDA
1 |
962,103
|
875,467
|
904,943
|
1,185,835
|
1,251,054
|
1,050,294
|
EBIT
1 |
834,841
|
747,361
|
767,386
|
1,034,226
|
1,094,573
|
894,749
|
Operating Margin
|
4.05%
|
3.36%
|
3.4%
|
4.03%
|
3.91%
|
3.14%
|
Earnings before Tax (EBT)
1 |
879,481
|
813,103
|
882,740
|
1,091,263
|
1,101,140
|
892,425
|
Net income
1 |
653,064
|
580,630
|
680,598
|
847,881
|
847,533
|
688,499
|
Net margin
|
3.17%
|
2.61%
|
3.02%
|
3.3%
|
3.02%
|
2.42%
|
EPS
2 |
241.1
|
214.4
|
251.3
|
313.0
|
312.9
|
254.2
|
Free Cash Flow
1 |
392,045
|
-112,331
|
673,874
|
150,176
|
-217,420
|
159,991
|
FCF margin
|
1.9%
|
-0.51%
|
2.99%
|
0.58%
|
-0.78%
|
0.56%
|
FCF Conversion (EBITDA)
|
40.75%
|
-
|
74.47%
|
12.66%
|
-
|
15.23%
|
FCF Conversion (Net income)
|
60.03%
|
-
|
99.01%
|
17.71%
|
-
|
23.24%
|
Dividend per Share
2 |
90.00
|
90.00
|
200.0
|
205.0
|
205.0
|
-
|
Announcement Date
|
19-03-29
|
20-04-03
|
21-03-29
|
22-03-31
|
23-03-28
|
24-03-28
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,426,966
|
1,177,686
|
1,765,657
|
1,555,016
|
869,025
|
546,107
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
392,045
|
-112,331
|
673,874
|
150,176
|
-217,420
|
159,991
|
ROE (net income / shareholders' equity)
|
12%
|
9.75%
|
10.7%
|
12.6%
|
12.1%
|
9.54%
|
ROA (Net income/ Total Assets)
|
6.63%
|
5.49%
|
5.35%
|
6.83%
|
6.8%
|
5.24%
|
Assets
1 |
9,855,787
|
10,583,462
|
12,712,427
|
12,423,167
|
12,470,870
|
13,148,068
|
Book Value Per Share
2 |
2,136
|
2,262
|
2,415
|
2,522
|
2,626
|
2,676
|
Cash Flow per Share
2 |
466.0
|
384.0
|
598.0
|
489.0
|
365.0
|
253.0
|
Capex
1 |
121,349
|
307,742
|
201,029
|
107,175
|
111,985
|
169,561
|
Capex / Sales
|
0.59%
|
1.38%
|
0.89%
|
0.42%
|
0.4%
|
0.59%
|
Announcement Date
|
19-03-29
|
20-04-03
|
21-03-29
|
22-03-31
|
23-03-28
|
24-03-28
|
|
1st Jan change
|
Capi.
|
---|
| -10.42% | 387M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|